Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 444, 805 (14 December 2006) | doi:10.1038/444805a; Published online 13 December 2006
In brief
The world's largest drug company is facing some turbulence after a large human trial of its cholesterol drug candidate torcetrapib was abandoned. The 2 December announcement that the trial would end, due to an unexpectedly high death rate among its participants, caused Pfizers's shares to fall from almost $28 to $25, knocking about $20 billion off its market capitulation.
To read this story in full you will need to login or make a payment (see right).